BioSpace News Archive

Optical biometry devices are used for intraocular lens power calculations in clinical practice. Optical biometry is very accurate and non-invasive automated procedure that measures the characteristics of the eyes automatically.

Royal Philips convenes the Annual General Meeting of Shareholders 2022 and publishes the agenda with explanatory notes.

Immunovia has appointed Jeff Borcherding as CEO of its US subsidiary Immunovia, Inc. He joins from Myriad Genetics, one of the leading diagnostic companies in the US, where he was Chief Marketing Officer.

NRx Pharmaceuticals, Inc., a clinical-stage, biopharmaceutical company announced that management will report year end 2021 financial results prior to the market open on March 31, 2022.

Taiho Pharmaceutical Co., Ltd. and Helsinn Group, announced that Taiho has been granted approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market the NK1 receptor antagonist antiemetic drug “Arokaris® I.V. Infusion 235mg” for gastrointestinal symptoms associated with cancer chemotherapy.

Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system disorders, announced that the Company has entered into a definitive agreement to acquire Sunosi® from Jazz Pharmaceuticals.

GE Healthcare has announced the first patient dosed in the Phase III clinical trial for a Positron Emission Tomography radiopharmaceutical imaging agent which aims to assist in the evaluation of adult patients with suspected Parkinsonian syndromes, support research and improve patient care.

Passage Bio, Inc., a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, announced that management will participate in the following upcoming virtual investor conferences.

Atea Pharmaceuticals, Inc. today presented two posters highlighting nonclinical data demonstrating the nonclinical safety of bemnifosbuvir (AT-527) at the Society of Toxicology (SOT) 61st Annual Meeting taking place in San Diego, California from March 27 – 31, 2022.

Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2021, and provided business highlights.